Insider Stock Trading History of Reid Laurence


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Reid Laurence since year 2005. The trader's CIK number is 1492749. At the time of this reporting, Reid Laurence is the SVP, Chief Business Officer of Alnylam Pharmaceuticals, Inc. . (stock ticker symbol ALNY). See this page for all insider trading activities at Alnylam Pharmaceuticals, Inc. .


Stock purchases, sales, and option exercises reported by insider Reid Laurence since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2014-12-31 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 17,000 15.99 271,830
2014-11-18 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 10,000 10.74 107,430
2014-11-18 ALNY Alnylam Pharmaceuticals, Inc. Sale 10,000 91.06 910,570
2014-08-18 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 13,500 8.12 109,619
2014-08-18 ALNY Alnylam Pharmaceuticals, Inc. Sale 13,500 67.32 908,793
2014-05-19 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 13,500 8.12 109,619
2014-05-19 ALNY Alnylam Pharmaceuticals, Inc. Sale 13,500 57.54 776,776
2014-02-19 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 13,500 11.54 155,857
2014-02-19 ALNY Alnylam Pharmaceuticals, Inc. Sale 20,400 80.24 1,636,794
2013-12-30 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 3,752 15.99 59,994
2013-11-13 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 13,500 15.99 215,865
2013-11-13 ALNY Alnylam Pharmaceuticals, Inc. Sale 13,500 53.36 720,306
2013-05-28 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 5,000 7.10 35,500
2013-05-28 ALNY Alnylam Pharmaceuticals, Inc. Sale 5,000 30.00 150,000
2013-02-08 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 5,000 7.10 35,500
2013-02-08 ALNY Alnylam Pharmaceuticals, Inc. Sale 5,000 25.00 125,000
2012-02-21 ALNY Alnylam Pharmaceuticals, Inc. Buy 930 10.75 9,997

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Reid Laurence (SVP, Chief Business Officer of Alnylam Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.